Acura Pharmaceuticals ACUR · USD

Its shares trade under the ticker ACUR. It has been listed since 12 September 2000. In the fiscal year to 31 December 2021, it reported revenue of $1.6m and a net loss of $879,000. At that date it held total assets of $860,000 and shareholders' equity of $178,000.

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. The firm is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The firm has discovered and developed three platform technologies, which can be used to develop multiple products. The firm's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The firm's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The firm's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Robert JonesPresident, Chief Executive Officer, Director, since 2008$150,000
• Mr. Robert SeiserSenior Vice President, Chief Financial Officer$196,948
• Dr. Albert BrzeczkoVice President - Pharmaceutical Sciences$220,000
• Mr. James EmighVice President - Corporate Development$196,948
• Mr. George RossIndependent Director$41,043
• Mr. William SkellyIndependent Director, since 1996$38,543
• Mr. Immanuel ThangarajIndependent Director$29,793

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.